

List of figures

Figure No.	Description	Page No.
Figure 1.1	Pathophysiological pathways of Alzheimer's disease	10
Figure 1.2	FDA approved AChE inhibitors for the treatment of Alzheimer's disease	14
Figure 1.3	NMDA receptor antagonist for the treatment of Alzheimer's disease	15
Figure 2.1	Hit(s) identification workflow by structure-based and ligand-based drug design	25
Figure 2.2	Cocrystal inhibitor structures from MMP-9 structure for the development of e-pharmacophore with their respective PDB, resolutions, and inhibitory activity (IC ₅₀ value /Ki value)	28
Figure 2.3	Alignment of all 155 ligands on the pharmacophore model AADHR of 3D-QSAR	32
Figure 2.4	MMP-9 binding site pockets (maroon) with cocrystal ligands (green) from five PDB codes, utilizing "create binding site surfaces"	47
Figure 2.5	e-Pharmacophore hypotheses with their respective PDB codes. A, hydrogen-bond acceptor, pink sphere with arrow; R, aromatic ring, yellow open circle; D, hydrogen-bond donor, blue sphere with the arrow; N, negative ionizable group, pink sphere	48
Figure 2.6	3D-QSAR based-pharmacophore hypotheses. A, hydrogen-bond acceptor, pink sphere with arrow; D, hydrogen-bond donor, blue sphere with arrow; R, aromatic ring, yellow open circle; H, hydrophobic group, green sphere	54
Figure 2.7	Plot of the observed pIC ₅₀ versus predicted pIC ₅₀ of MMP-9 inhibitors from the model AADHR obtained by using 124 training set ligands and validated by using 31 test set ligands. Red dot line represents regression line for the training set, blue dot line for test set and green dot line for training set of compounds when intercept set as zero. The equation is the best fit line of training set	54
Figure 2.8	Contour maps of most active (left) and least active (right) known MMP-9 inhibitors. Hydrogen-bond donor effect, most active, A & least active, B (blue for favorable; red for unfavorable); non-polar effect, most active, C & least active, D (orange-yellow, favorable; purple, unfavorable); electron-withdrawing effect, most active, E; and least active, F (yellow, favorable; maroon, unfavorable)	55
Figure 2.9	The HOMO map of most active inhibitor, A; least active inhibitor, B; and hit (H-7), C; the LUMO of most active, D; least active, E; and H-7, F; and molecular electrostatic potential	63

	(MESP) picture of most active, G; least active, H; and H-7, I	
Figure 2.10	Structure of N73 and final hits with selective MMP-9 binding affinity	64
Figure 2.11	Selected hits for <i>in vitro</i> studies	65
Figure 2.12	Dose-response curves of hits with reference NNGH against MMP-9	66
Figure 2.13	Linear correlations between experimental and reported permeability of commercial drugs for PAMPA-BBB assay	67
Figure 2.14	RMSD plot of RMSD values (N73-4XCT and ZINC21212924-4XCT complexes) for protein on the left Y-axis and for ligand on the right Y-axis; protein backbone in green, and ligand in maroon	70
Figure 2.15	RMSF of the protein C- α chain in N73-4XCT and ZINC21212924-4XCT complexes	71
Figure 2.16	Schematic diagrams of detailed ligand (N73 and ZINC21212924) interactions with amino acid residues of MMP-9 after MD simulation	71
Figure 3.1	Flowchart of hit(s) identification based on ligand-based and structure-based pharmacophore models	85
Figure 3.2	Alignment of all 142 AChE inhibitors with developed pharmacophore hypothesis	87
Figure 3.3	Structures of cocrystal ligand with PDB id and resolution	87
Figure 3.4	3D-QSAR pharmacophore hypotheses and structure-based pharmacophores models with their respective crystal structures. A, H-bond acceptor, Pink sphere containing arrow; D, H-bond donor, sky blue sphere with arrow; H, hydrophobic group, green sphere; P, positive ionizable group, violet sphere; R, aromatic ring, yellow circle	97
Figure 3.5	Plot of predicted pIC ₅₀ versus observed pIC ₅₀ of AChE inhibitors developed by model HPRRR with regression lines (original regression lines represented in green break line and regression lines with intercept zero in purple break line)	98
Figure 3.6	Crystal structures of AChE with cocrystal ligands (purple) and bonding interactions	98
Figure 3.7	Structures of final selected hits with Zinc database ids	103
Figure 3.8	Docking poses of ZINC72451013, ZINC20649934, ZINC05354646, ZINC79331983, ZINC20592007, ZINC77161317, ZINC58160603, and ZINC39154782 with AChE crystal structure; hits represented in yellowish green, residues in gray, H-bond in red, pi-cationic interaction in green and pi-pi stacking in cyan	104
Figure 3.9	Docking pose of four hits with 4M0E crystal structure using AutoDock (purple arrow indicates H-bond; green line denotes π - π	106

	stacking; red line for pi-cationic interactions	
Figure 3.10	Docking pose of another four hits with 4M0E crystal structure using AutoDock (purple arrow indicates H-bond; green line denotes π - π stacking; red line for pi-cationic interactions)	107
Figure 3.11	Dose-response curves of selected hits with donepezil	111
Figure 3.12	Lineweaver-Burk plots from substrate-velocity curves of AChE activity with different substrate concentrations (0.15–1.15 μ M) in absence and presence of 0.25, 0.5 and 1 μ M of ZINC20592007	112
Figure 3.13	Lineweaver-Burk plots from substrate-velocity curves of AChE activity with different substrate concentrations (0.15–1.15 μ M) in absence and presence of 0.25, 0.5 and 1 μ M of ZINC05354646	112
Figure 3.14	Lineweaver-Burk plots from substrate-velocity curves of AChE activity with different substrate concentrations (0.15–1.15 μ M) in absence and presence of 0.5, 1 and 2 μ M of ZINC20649934	113
Figure 3.15	Lineweaver-Burk plots from substrate-velocity curves of AChE activity with different substrate concentrations (0.15–1.15 μ M) in absence and presence of 0.5, 1 and 2 μ M of ZINC39154782	113
Figure 3.16	RMSD plot of RMSD values (donepezil-AChE, ZINC20592007-AChE, and ZINC20649934-AChE complexes) for protein on the left Y-axis and ligand on the right Y-axis; protein backbone in green, and ligand in maroon	117
Figure 3.17	RMSF of the protein C- α chain in donepezil-AChE, ZINC20592007-AChE, and ZINC20649934-AChE complexes	118
Figure 3.18	Ligand interactions with amino acid residues of AChE after MD	118
Figure 4.1	Crystal structures of tau-tubulin kinase 1: A Structure of TTBK1 with the clarification of different regions present in enzyme protein utilizing PDB id: 4NFN; B Superimposed structures of TTBK1-2KC complex (PDB id: 4NFN), and apoprotein TTBK1 (PDB id: 4NFM)	127
Figure 4.2	Schematic representation of hits identification process as tau-tubulin kinase 1 inhibitor	127
Figure 4.3	Structures of cocrystal ligands with their PDB ids and resolutions	128
Figure 4.4	Residues of crystal structures of tau-tubulin kinase 1 involved with binding interactions of cocrystal ligands (yellowish green).	134
Figure 4.5	e-Pharmacophore models with respective crystal structures. ‘A’ denotes hydrogen bond acceptor, pink sphere with arrow; ‘D’ indicates hydrogen bond donor, sky blue sphere containing arrow; ‘R’ denotes aromatic ring, yellow circle	135
Figure 4.6	Structures (with Zinc database ids) of final identified hits as tau-tubulin kinase 1 inhibitors	138
Figure 4.7	Representations for cocrystal ligand 2KC: A, Glide XP docking pose (ligand in yellow); B, Induced fit docking pose (ligand in	139

	cyan); C, Glide XP docking 2d pose; D, TTBK1 protein's residue interactions with 2KC after MD simulations, E, RMSD plot of RMSD values for protein on the left y-axis and ligand on right y-axis were displayed, protein backbone in bottle green color, and ligand in maroon; F, RMSF of the protein C- α chain in 2KC-TTBK1 complex	
Figure 4.8	Representation for cocrystal ligand ZINC14644839: A, Glide XP docking pose (ligand in yellow); B, Induced Fit docking pose (ligand in cyan); C, Glide XP docking 2d pose; D, TTBK1 protein's residue interactions with ZINC14644839 after MD simulations; E, RMSD plot of RMSD values for protein on the left y-axis and ligand on right y-axis were displayed, protein backbone in bottle green, and ligand in maroon. F, RMSF of the protein C- α chain in ZINC14644839-TTBK1 complex	140
Figure 4.9	Representation for co-crystal ligand ZINC00012956: A, Glide XP docking pose (ligand in yellow); B, Induced Fit docking pose (ligand in cyan); C, Glide XP docking 2d pose; D, TTBK1 protein's residue interactions with ZINC00012956 after MD simulations; E, RMSD plot of RMSD values for protein on the left y-axis and ligand on right y-axis were displayed, protein backbone in bottle green, and ligand in maroon. F, RMSF of the protein C- α chain in ZINC00012956-TTBK1 complex	141
Figure 4.10	Representation for cocrystal ligand ZINC91332506: A, Glide XP docking pose (ligand in yellow); B, Induced Fit docking pose (ligand in cyan); C, Glide XP docking 2d pose; D, TTBK1 protein's residue interactions with ZINC91332506 after MD simulations; E, RMSD plot of RMSD values for protein on the left y-axis and ligand on right y-axis were displayed, protein backbone in bottle green, and ligand in maroon. F, RMSF of the protein C- α chain in ZINC91332506-TTBK1 complex.	142
Figure 4.11	Representation for cocrystal ligand ZINC69775110: A, Glide XP docking pose (ligand in yellow); B, Induced Fit docking pose (ligand in cyan); C, Glide XP docking 2d pose; D, TTBK1 protein's residue interactions with ZINC69775110 after MD simulations; E, RMSD plot of RMSD values for protein on the left y-axis and ligand on right y-axis were displayed, protein backbone in bottle green, and ligand in maroon; F, RMSF of the protein C- α chain in ZINC69775110-TTBK1 complex	143
Figure 5.1	Irreversible (I), reversible (R), and selective MAO-A or MAO-B (A or B) inhibitors.	153
Figure 5.2	Plausible mechanism of 4-oxo-N, 4-diphenylbutanamides synthesis from (E)-4-hydroxy-4-phenylbut-2-enoic acid	160
Figure 5.3	Docking pose of fragments with interacting amino acid residues	179

	of AChE	
Figure 5.4	Docking pose of fragments with interacting amino acid residues of MAO-B	180
Figure 5.5	Rationale for designed molecule as MAO and AChE inhibitor	181
Figure 5.6	HPLC Chromatogram (t_R , 3.007 min) of compound 6h at 250 nm	188
Figure 5.7	HPLC Chromatogram (t_R , 2.847 min) of compound 7h at 250 nm	188
Figure 5.8	Linear correlation chart of experimental and literature reported permeability of commercial drugs for PAMPA-BBB assay.	192
Figure 5.9	MD simulations of compound 6m with AChE: A, Docking pose after MD; B, RMSF curve for C-alphas; C, protein and ligand RMSD curve	198
Figure 5.10	MD simulations of compound 6n with MAO-B: A, Docking pose after MD; B, RMSF curve for C-alphas; C, protein and ligand RMSD curve	198
Figure 5.11	MD simulations of compound 7k with MAO-B: A, Docking pose after MD; B, RMSF curve for C-alphas; C, protein and ligand RMSD curve	199
Figure 5.12	MD simulations of compound 7p with MMP-9: A, Docking pose after MD; B, RMSF curve for C-alphas; C, protein and ligand RMSD curve	199
Figure A.1	Known MMP-9 inhibitors for development of 3D-QSAR models	207
Figure A.2	Total 24 hits from Zinc15 database as MMP-9 inhibitor (selective and non-selective)	219
Figure A.3	Binding pose of H-1 to H-12 in the active site pocket of MMP-9	220
Figure A.4	Binding pose of H-13 to H-24 at the active site pocket of MMP-9	221
Figure A.5	List of AChE Inhibitors used for development of 3D-QSAR model	222
Figure A.6	^1H NMR spectrum of compound 6C in DMSO- d_6	237
Figure A.7	^{13}C NMR spectrum of compound 6C in DMSO- d_6	237
Figure A.8	^1H NMR spectrum of compound 7k in DMSO- d_6	238
Figure A.9	^{13}C NMR spectrum of compound 7k in DMSO- d_6	238
Figure A.10	FTIR spectra of compound 6h	239
Figure A.11	FTIR spectra of compound 7k	239
Figure A.12	Mass spectra of Compound 7k	240